Company intelligence / Profile preview

CellabMED

Ownership: Private
Development stage: Other

Overview

CellabMED is developing CAR-T cell therapies for rare and intractable cancers, with their lead product CLM-103 having received IND approval in 2021. The company has secured multiple patent registrations across different countries for CLM-103.

Therapeutic areas: OncologyRare Diseases
Modalities: CAR-T cell therapyTherapeutic antibodiesCell and gene therapies
Industry: Biotech

Drug pipeline

1 asset

yyb101

Partnerships

HK InnoenSG MedicalKorea University's College of MedicineThe University of New South Wales (UNSW)

Beyond the preview

Go deeper on CellabMED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellabMED.

Explore the full profile